HomeAboutRankingsData Sources
© 2026 GeneE
🧬
GeneE
10 sources retrieved · Most recent: April 2026 · Index updated 14 days ago
ⓘGeneE is for informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment.
SSTR5
somatostatin receptor 5
Chromosome 16 · 16p13.3
NCBI Gene: 6755Ensembl: ENSG00000162009.11HGNC: HGNC:11334UniProt: P35346
111PubMed Papers
20Diseases
11Drugs
0Pathogenic Variants
FUNCTIONAL ROLE
Receptor
CLINICAL
FDA Approved Target
DATA QUALITY
✓ Experimental GO Evidence✓ Swiss-Prot Reviewed
plasma membranepositive regulation of cytokinesisprotein bindingneuropeptide signaling pathwayacromegalyneoplasmneuroendocrine neoplasmpituitary-dependent Cushing's disease
✦AI Summary

SSTR5 (somatostatin receptor 5) is a G-protein coupled receptor that binds somatostatin 28 and, to a lesser extent, somatostatin-14, mediating signaling through inhibition of adenylyl cyclase 1. The receptor is expressed in various tissues including the pituitary, where SSTR2 and SSTR5 predominate and regulate hormone secretion and cell growth 1. SSTR5 is also present in peripheral tissues such as thoracic duct smooth muscle cells 2 and cardiac tissue, where expression is significantly decreased in ischemic cardiomyopathy 3. In neuroendocrine tumors, SSTR5 expression serves as both a diagnostic marker and therapeutic target. Elevated SSTR5 mRNA levels in peripheral blood show high sensitivity (86%) for detecting neuroendocrine lung cancers 4. In pancreatic insulinomas, SSTR5 expression occurs in only 6% of cases but is associated with impaired overall survival 5. Functionally, SSTR5 can enhance the growth inhibitory effects of SSTR2 through heterodimerization and plays a role in mediating responses to glucocorticoid receptor modulators in pituitary tumors 6. The receptor's expression is linked to epithelial-mesenchymal transition and neuroendocrine differentiation in pancreatic cancer cells 7.

Sources cited
1
SSTR5 is a G-protein coupled receptor expressed in pituitary that regulates hormone secretion and cell growth
PMID: 20149677
2
SSTR5 is present in thoracic duct smooth muscle cells
PMID: 21667819
3
SSTR5 expression is significantly decreased in ischemic cardiomyopathy
PMID: 39038008
4
SSTR5 mRNA in peripheral blood shows 86% sensitivity for detecting neuroendocrine lung cancers
PMID: 21503779
5
SSTR5 expression in insulinomas occurs in 6% of cases and is associated with impaired survival
PMID: 36680557
6
SSTR5 mediates responses to glucocorticoid receptor modulators in pituitary tumors
PMID: 36640905
7
SSTR5 expression is linked to epithelial-mesenchymal transition in pancreatic cancer cells
PMID: 39682758
Disease Associationsⓘ20
acromegalyOpen Targets
0.61Moderate
neoplasmOpen Targets
0.59Moderate
neuroendocrine neoplasmOpen Targets
0.56Moderate
pituitary-dependent Cushing's diseaseOpen Targets
0.52Moderate
carcinoid tumorOpen Targets
0.52Moderate
carcinoid syndromeOpen Targets
0.45Moderate
neurodegenerative diseaseOpen Targets
0.45Moderate
neuroendocrine carcinomaOpen Targets
0.41Moderate
cancerOpen Targets
0.39Weak
hepatocellular carcinomaOpen Targets
0.38Weak
digestive system neuroendocrine neoplasmOpen Targets
0.37Weak
Autosomal dominant polycystic kidney diseaseOpen Targets
0.37Weak
metastasisOpen Targets
0.37Weak
diabetic retinopathyOpen Targets
0.36Weak
DiarrheaOpen Targets
0.34Weak
pancreatic carcinomaOpen Targets
0.33Weak
neuroinflammatory disorderOpen Targets
0.29Weak
Pituitary Gland AdenomaOpen Targets
0.29Weak
breast cancerOpen Targets
0.29Weak
pancreatic neuroendocrine tumorOpen Targets
0.28Weak
Pathogenic Variants
No pathogenic variants reported on ClinVar for this gene.
View on ClinVar ↗
Drug Targets11
LANREOTIDEPhase III
Somatostatin receptor 2 agonist
acromegaly
LANREOTIDE ACETATEApproved
Somatostatin receptor 2 agonist
acromegaly
LUTETIUM OXODOTREOTIDE LU-177Approved
Somatostatin receptor binding agent
neuroendocrine neoplasm
OCTREOTIDEApproved
Somatostatin receptor agonist
acromegaly
OCTREOTIDE ACETATEApproved
Somatostatin receptor agonist
ONZIGOLIDEPhase III
Somatostatin receptor 2 agonist
psoriasis vulgaris
PASIREOTIDEApproved
Somatostatin receptor 2 agonist
PASIREOTIDE DIASPARTATEPhase II
Somatostatin receptor 3 agonist
Hypoglycemia
PASIREOTIDE PAMOATEApproved
Somatostatin receptor 2 agonist
SOMATOSTATINPhase III
Somatostatin receptor agonist
Autosomal dominant polycystic kidney disease
VELDOREOTIDEPhase II
Somatostatin receptor 2 agonist
acromegaly
Related Genes
DRD2Protein interaction95%GNAI1Protein interaction92%GNAI2Protein interaction91%GNAI3Protein interaction91%SSTR2Protein interaction86%NPYProtein interaction75%
Tissue Expression6 tissues
Brain
100%
Lung
0%
Bone Marrow
0%
Ovary
0%
Heart
0%
Liver
0%
Gene Interaction Network
Click a node to explore
SSTR5DRD2GNAI1GNAI2GNAI3SSTR2NPY
PROTEIN STRUCTURE
Preparing viewer…
PDB8X8L · 2.70 Å · EM
View on RCSB ↗
Constraintⓘ
LOEUFⓘ
1.93LoF Tolerant
pLIⓘ
0.12Tolerant
Observed/Expected LoF2.30 [0.35–1.93]
RankingsWhere SSTR5 stands among ~20K protein-coding genes
  • #4,296of 20,598
    Most Researched111 · top quartile
  • #270of 1,025
    FDA-Approved Drug Targets6
  • #17,484of 17,882
    Most Constrained (LOEUF)1.93
Genes detectedSSTR5
Sources retrieved10 papers
Response time—
📄 Sources
10▼
1
Genetically engineered human pituitary corticotroph tumor organoids exhibit divergent responses to glucocorticoid receptor modulators.
PMID: 36640905
Transl Res · 2023
1.00
2
Gene expression of somatostatin receptor subtypes SSTR2a, SSTR3 and SSTR5 in peripheral blood of neuroendocrine lung cancer affected patients.
PMID: 21503779
Cell Oncol (Dordr) · 2011
0.90
3
Somatostatin receptors SSTR2 and SSTR5 are expressed in the human thoracic duct.
PMID: 21667819
Lymphology · 2011
0.80
4
Pituitary somatostatin receptor signaling.
PMID: 20149677
Trends Endocrinol Metab · 2010
0.70
5
Somatostatin receptors in fibrotic myocardium.
PMID: 39038008
PLoS One · 2024
0.60